Public health paradoxes and the epidemiological impact of an HPV vaccine

被引:49
作者
Garnett, GP [1 ]
Waddell, HC [1 ]
机构
[1] Univ Oxford, Wellcome Trust Ctr Epidemiol Infect Dis, S Parks Rd, Oxford OX1 2JD, England
关键词
D O I
10.1016/S1386-6532(00)00129-3
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Background: our understanding of human papilloma virus (HPV) and cervical cancer has improved dramatically, with a vaccine against the viral infection being a real possibility in the near future. Aims: the goal of an HPV vaccine would be to reduce the prevalence of infection and hence the risk of cervical abnormalities. However, questions arise as to how this would interact with an existing intervention, screening, which reduces the progress of cervical abnormalities to serious disease. Furthermore, will a vaccine against one genotype influence the other types within a population and will the patterns of infection and disease remain the same if the vaccine alters the timing and type of HPVs experienced within a population? What would a vaccine that only worked in one sex achieve and how widespread would the use of such a vaccine have to be? Conclusion: the above-given questions can be addressed within a theoretical framework that describes the transmission dynamics of human papilloma virus. (C) 2000 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:101 / 111
页数:11
相关论文
共 43 条
[1]  
ANDERSON R M, 1991
[2]  
Aylward RB, 2000, B WORLD HEALTH ORGAN, V78, P285
[3]  
Beers MarkH., 1999, MERCK MANUAL DIAGNOS, V17th
[4]   PREVALENCE OF HUMAN PAPILLOMAVIRUS IN CERVICAL-CANCER - A WORLDWIDE PERSPECTIVE [J].
BOSCH, FX ;
MANOS, MM ;
MUNOZ, N ;
SHERMAN, M ;
JANSEN, AM ;
PETO, J ;
SCHIFFMAN, MH ;
MORENO, V ;
KURMAN, R ;
SHAH, KV ;
ALIHONOU, E ;
BAYO, S ;
MOKHTAR, HC ;
CHICAREON, S ;
DAUDT, A ;
DELOSRIOS, E ;
GHADIRIAN, P ;
KITINYA, JN ;
KOULIBALY, M ;
NGELANGEL, C ;
TINTORE, LMP ;
RIOSDALENZ, JL ;
SARJADI ;
SCHNEIDER, A ;
TAFUR, L ;
TEYSSIE, AR ;
ROLON, PA ;
TORROELLA, M ;
TAPIA, AV ;
WABINGA, HR ;
ZATONSKI, W ;
SYLLA, B ;
VIZCAINO, P ;
MAGNIN, D ;
KALDOR, J ;
GREER, C ;
WHEELER, C .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1995, 87 (11) :796-802
[5]   The influence of behavioural heterogeneity on the population level effect of potential prophylactic type 1 human immunodeficiency virus vaccines [J].
Garnett, GP .
JOURNAL OF THE ROYAL STATISTICAL SOCIETY SERIES A-STATISTICS IN SOCIETY, 1998, 161 :209-225
[6]  
Garnett GP, 1996, REV MED VIROL, V6, P151, DOI 10.1002/(SICI)1099-1654(199609)6:3&lt
[7]  
151::AID-RMV172&gt
[8]  
3.0.CO
[9]  
2-V
[10]  
Heyward WL, 1998, AIDS RES HUM RETROV, V14, pS205